Clinical Trial Update: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) [Phase 2]

View source ↗

Summary

An extension study of ABBV-8E12 in progressive supranuclear palsy (PSP) was terminated after Phase 2; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• ABBV-8E12 (ABBV-8E12)

Snippet

Sponsor: AbbVie | Conditions: Progressive Supranuclear Palsy (PSP) | Phase 2 | Status: TERMINATED | Results posted: 2021-02-03